C. elegans for anti-infective discovery

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 769-774

  Arvanitis, Marios ^a   Glavis Bloom, Justin ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AVERMECTIN DERIVATIVE; BERBERINE; CINNAMALDEHYDE DERIVATIVE; ESCULETIN; INDOLE DERIVATIVE; NATURAL PRODUCT; PROBIOTIC AGENT; RALOXIFENE; TOBRAMYCIN; TUNICAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BIOFILM; CAENORHABDITIS ELEGANS; CANDIDA ALBICANS; DISEASE MODEL; DRUG SCREENING; ENTEROCOCCUS FAECALIS; HIGH THROUGHPUT SCREENING; IMMUNE RESPONSE; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS;

EID: 84892967261     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.08.002     Document Type: Review

References (51)

1. Canton R, Bryan J: Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance. Expert Rev Anti Infect Ther 2012, 10: 1269-1271.
2. Master RN, Deane J, Opiela C, Sahm DF: Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci 2013, 1277: 1-7.
3. Spellberg B, Bartlett JG, Gilbert DN: The future of antibiotics and resistance. N Engl J Med 2013, 368: 299-302.
4. Da Silva GJ, Mendonca N: Association between antimicrobial resistance and virulence in Escherichia coli. Virulence 2012, 3: 18-28.
5. Cottell JL, Webber MA, Piddock LJ: Persistence of transferable extended-spectrum-beta-lactamase resistance in the absence of antibiotic pressure. Antimicrob Agents Chemother 2012, 56: 4703-4706.
6. Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pages JM, Nicolas-Chanoine MH: Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob Agents Chemother 2010, 54: 4373-4378.
7. Mylonakis E, Aballay A: Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect Immun 2005, 73: 3833-3841. (Pubitemid 40923120)
8. Anastassopoulou CG, Fuchs BB, Mylonakis E: Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des 2011, 17: 1225-1233.
9. Consortium CeS: Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 1998, 282: 2012-2018.
10. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM: Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 2006, 103: 10414-10419. (Pubitemid 44051181)
11. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E: Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 2007, 3:e18.
12. Tampakakis E, Okoli I, Mylonakis E: A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protoc 2008, 3: 1925-1931.
13. Uccelletti D, Zanni E, Marcellini L, Palleschi C, Barra D, Mangoni ML: Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: a plausible mode of action in vitro and in vivo. Antimicrob Agents Chemother 2010, 54: 3853-3860.
14. Bolhuis A, Hand L, Marshall JE, Richards AD, Rodger A, Aldrich-Wright J: Antimicrobial activity of ruthenium-based intercalators. Eur J Pharm Sci 2011, 42: 313-317.
15. Thevissen K, Pellens K, De Brucker K, Francois IE, Chow KK, Meert EM, Meert W, Van Minnebruggen G, Borgers M, Vroome V et al.: Novel fungicidal benzylsulfanyl-phenylguanidines. Bioorg Med Chem Lett 2011, 21: 3686-3692.
16. Borges WS, Mancilla G, Guimaraes DO, Duran-Patron R, Collado IG, Pupo MT: Azaphilones from the endophyte Chaetomium globosum. J Nat Prod 2011, 74: 1182-1187.
17. Cho SC, Park MC, Keam B, Choi JM, Cho Y, Hyun S, Park SC, Lee J: DDS, 4,40-diaminodiphenylsulfone, extends organismic lifespan. Proc Natl Acad Sci U S A 2010, 107: 19326-19331.
18. Li Z, Nair SK: Quorum sensing: how bacteria can coordinate activity and synchronize their response to external signals? Protein Sci 2012, 21: 1403-1417.
19. Vendeville A, Winzer K, Heurlier K, Tang CM, Hardie KR: Making 'sense' of metabolism: autoinducer-2. LuxS and pathogenic bacteria. Nat Rev Microbiol 2005, 3: 383-396. (Pubitemid 40590381)
20. Galloway WR, Hodgkinson JT, Bowden SD, Welch M, Spring DR: Quorum sensing in Gram-negative bacteria: small-molecule modulation of AHL and AI-2 quorum sensing pathways. Chem Rev 2011, 111: 28-67.
21. Brackman G, Celen S, Hillaert U, Van Calenbergh S, Cos P, Maes L, Nelis HJ, Coenye T: Structure-activity relationship of cinnamaldehyde analogs as inhibitors of AI-2 based quorum sensing and their effect on virulence of Vibrio spp. PLoS ONE 2011, 6:e16084.
22. Lee KM, Lim J, Nam S, Yoon MY, Kwon YK, Jung BY, Park Y, Park S, Yoon SS: Inhibitory effects of broccoli extract on Escherichia coli O157:H7 quorum sensing and in vivo virulence. FEMS Microbiol Lett 2011, 321: 67-74.
23. Kim Y, Lee JW, Kang SG, Oh S, Griffiths MW: Bifidobacterium spp. influences the production of autoinducer-2 and biofilm formation by Escherichia coli O157:H7. Anaerobe 2012, 18: 539-545.
24. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T: Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother 2011, 55: 2655-2661.
25. Christensen LD, van Gennip M, Jakobsen TH, Alhede M, Hougen HP, Hoiby N, Bjarnsholt T, Givskov M: Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother 2012, 67: 1198-1206.
26. Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, Izano EA: Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 2012, 65: 73-77.
27. Ho Sui SJ, Lo R, Fernandes AR, Caulfield MD, Lerman JA, Xie L, Bourne PE, Baillie DL, Brinkman FS: Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int J Antimicrob Agents 2012, 40: 246-251.
28. Lee JH, Cho HS, Kim Y, Kim JA, Banskota S, Cho MH, Lee J: Indole and 7-benzyloxyindole attenuate the virulence of Staphylococcus aureus. Appl Microbiol Biotechnol 2013 http://dx.doi.org/10.1007/s00253-012-4674-z.
29. Swem LR, Swem DL, O'Loughlin CT, Gatmaitan R, Zhao B, Ulrich SM, Bassler BL: A quorum-sensing antagonist targets both membrane-bound and cytoplasmic receptors and controls bacterial pathogenicity. Mol Cell 2009, 35: 143-153.
30. Maeda T, Garcia-Contreras R, Pu M, Sheng L, Garcia LR, Tomas M, Wood TK: Quorum quenching quandary: resistance to antivirulence compounds. ISME J 2012, 6: 493-501.
31. Pukkila-Worley R, Feinbaum R, Kirienko NV, Larkins-Ford J, Conery AL, Ausubel FM: Stimulation of host immune defenses by a small molecule protects C. elegans from bacterial infection. PLoS Genet 2012, 8:e1002733.
32. Dharmalingam K, Tan BK, Mahmud MZ, Sedek SA, Majid MI, Kuah MK, Sulaiman SF, Ooi KL, Khan NA, Muhammad TS et al.: Swietenia macrophylla extract promotes the ability of Caenorhabditis elegans to survive Pseudomonas aeruginosa infection. J Ethnopharmacol 2012, 139: 657-663.
33. Kandasamy S, Khan W, Evans F, Critchley AT, Prithiviraj B: Tasco(R): a product of Ascophyllum nodosum enhances immune response of Caenorhabditis elegans against Pseudomonas aeruginosa infection. Mar Drugs 2012, 10: 84-105.
34. Kim Y, Mylonakis E: Caenorhabditis elegans immune conditioning with the probiotic bacterium Lactobacillus acidophilus strain NCFM enhances gram-positive immune responses. Infect Immun 2012, 80: 2500-2508.
35. Montalvo-Katz S, Huang H, Appel MD, Berg M, Shapira M: Association with soil bacteria enhances p38-dependent infection resistance in Caenorhabditis elegans. Infect Immun 2013, 81: 514-520.
36. Tomkiewicz D, Casadei G, Larkins-Ford J, Moy TI, Garner J, Bremner JB, Ausubel FM, Lewis K, Kelso MJ: Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components. Antimicrob Agents Chemother 2010, 54: 3219-3224.
37. Suzuki T, Campbell J, Kim Y, Swoboda JG, Mylonakis E, Walker S, Gilmore MS: Wall teichoic acid protects Staphylococcus aureus from inhibition by Congo red and other dyes. J Antimicrob Chemother 2012, 67: 2143-2151.
38. Wahlby C, Kamentsky L, Liu ZH, Riklin-Raviv T, Conery AL, O'Rourke EJ, Sokolnicki KL, Visvikis O, Ljosa V, Irazoqui JE et al.: An image analysis toolbox for high-throughput C. elegans assays. Nat Methods 2012, 9: 714-716.
39. Raviv TR, Ljosa V, Conery AL, Ausubel FM, Carpenter AE, Golland P, Wahlby C: Morphology-guided graph search for untangling objects: C. elegans analysis. Med Image Comput Comput Assist Interv 2010, 13: 634-641.
40. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, Casadei G, Lewis K, Carpenter AE, Ausubel FM: High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 2009, 4: 527-533.
41. Coleman JJ, Okoli I, Tegos GP, Holson EB, Wagner FF, Hamblin MR, Mylonakis E: Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol 2010, 5: 321-332.
42. Coleman JJ, Ghosh S, Okoli I, Mylonakis E: Antifungal activity of microbial secondary metabolites. PLoS ONE 2011:6e25321.
43. Okoli I, Coleman JJ, Tampakakis E, An WF, Holson E, Wagner F, Conery AL, Larkins-Ford J, Wu G, Stern A et al.: Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS ONE 2009, 4:e7025.
44. Zhou YM, Shao L, Li JA, Han LZ, Cai WJ, Zhu CB, Chen DJ: An efficient and novel screening model for assessing the bioactivity of extracts against multidrug-resistant Pseudomonas aeruginosa using Caenorhabditis elegans. Biosci Biotechnol Biochem 2011, 75: 1746-1751.
45. Kaewintajuk K, Cho PY, Kim SY, Lee ES, Lee HK, Choi EB, Park H: Anthelmintic activity of KSI-4088 against Caenorhabditis elegans. Parasitol Res 2010, 107: 27-30.
46. Yan S, Bleuler-Martinez S, Plaza DF, Kunzler M, Aebi M, Joachim A, Razzazi-Fazeli E, Jantsch V, Geyer R, Wilson IB et al.: Galactosylated fucose epitopes in nematodes: increased expression in a Caenorhabditis mutant associated with altered lectin sensitivity and occurrence in parasitic species. J Biol Chem 2012, 287: 28276-28290.
47. Crisford A, Murray C, O'Connor V, Edwards RJ, Kruger N, Welz C, von Samson-Himmelstjerna G, Harder A, Walker RJ, Holden-Dye L: Selective toxicity of the anthelmintic emodepside revealed by heterologous expression of human KCNMA1 in Caenorhabditis elegans. Mol Pharmacol 2011, 79: 1031-1043.
48. Hu Y, Platzer EG, Bellier A, Aroian RV: Discovery of a highly synergistic anthelmintic combination that shows mutual hypersusceptibility. Proc Natl Acad Sci U S A 2010, 107: 5955-5960.
49. Ghosh R, Andersen EC, Shapiro JA, Gerke JP, Kruglyak L: Natural variation in a chloride channel subunit confers avermectin resistance in C. elegans. Science 2012, 335: 574-578.
50. Carr JA, Parashar A, Gibson R, Robertson AP, Martin RJ, Pandey S: A microfluidic platform for high-sensitivity, real-time drug screening on C. elegans and parasitic nematodes. Lab Chip 2011, 11: 2385-2396.
51. Lockery SR, Hulme SE, Roberts WM, Robinson KJ, Laromaine A, Lindsay TH, Whitesides GM, Weeks JC: A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans. Lab Chip 2012, 12: 2211-2220.